Literature DB >> 10192826

Guanfacine, but not clonidine, improves planning and working memory performance in humans.

P Jäkälä1, M Riekkinen, J Sirviö, E Koivisto, K Kejonen, M Vanhanen, P Riekkinen.   

Abstract

The present study compares, using a double-blind, placebo controlled design the effects of two alpha 2-agonists, clonidine (0.5, 2, and 5 micrograms/kg) and guanfacine (7 and 29 micrograms/kg) on spatial working memory, planning and attentional set-shifting, functions thought to be dependent on the "central executive" of the prefrontal cortex. Blood pressure and the subjective feeling of sedation were affected equally by clonidine and guanfacine. The 0.5 microgram/kg and 5 micrograms/kg doses of clonidine disrupted spatial working memory, but the medium dose had no effect. The 0.5 and 2 micrograms/kg doses of clonidine increased impulsive responding in the planning test. The 5 micrograms/kg dose of clonidine slowed responding at effortful levels of planning and attentional set-shifting tests. The 29 micrograms/kg dose of guanfacine improved spatial working memory and planning. Guanfacine had no effect on attentional set-shifting. These data indicate that guanfacine improved planning and spatial working memory, but clonidine dose-dependently disrupted performance. It is possible that the greater selectivity of guanfacine for alpha 2A-adrenoceptor subtype may underlie its differences from clonidine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10192826     DOI: 10.1016/S0893-133X(98)00127-4

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  60 in total

Review 1.  The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Amy F T Arnsten
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

Review 2.  Hemispatial neglect.

Authors:  A Parton; P Malhotra; M Husain
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-01       Impact factor: 10.154

Review 3.  Cognitive enhancement as a treatment for drug addictions.

Authors:  Mehmet Sofuoglu; Elise E DeVito; Andrew J Waters; Kathleen M Carroll
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

Review 4.  A neurochemical yin and yang: does serotonin activate and norepinephrine deactivate the prefrontal cortex?

Authors:  Paul J Fitzgerald
Journal:  Psychopharmacology (Berl)       Date:  2010-04-13       Impact factor: 4.530

5.  New developments in the treatment of attention-deficit/hyperactivity disorder in primary care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 6.  Adrenergic pharmacology and cognition: focus on the prefrontal cortex.

Authors:  Brian P Ramos; Amy F T Arnsten
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

Review 7.  Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder.

Authors:  Craig W Berridge; David M Devilbiss
Journal:  Biol Psychiatry       Date:  2010-09-26       Impact factor: 13.382

8.  Preclinical evaluation of reconsolidation blockade by clonidine as a potential novel treatment for posttraumatic stress disorder.

Authors:  Karine Gamache; Roger K Pitman; Karim Nader
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

9.  Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates.

Authors:  Emmanuel Decamp; Kathryn Clark; Jay S Schneider
Journal:  Eur J Neurosci       Date:  2011-08-23       Impact factor: 3.386

10.  Lack of effects of guanfacine on executive and memory functions in healthy male volunteers.

Authors:  Ulrich Müller; Luke Clark; Minh L Lam; Rebecca M Moore; C Louise Murphy; Nicola K Richmond; Ranbir S Sandhu; Ingrid A Wilkins; David K Menon; Barbara J Sahakian; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.